Researchers presenting at the American Academy of Allergy, Asthma & Immunology Annual Meeting in Philadelphia last month reported early success with a novel protocol that induced sustained tolerance to peanut and cashew in three infants previously diagnosed with severe allergies.
The approach, known as the KIC-IT (Keep Introducing Consistently to Induce Tolerance) Protocol, takes advantage of the reduced allergenicity of minimally processed (raw) nuts before transitioning patients to roasted forms. The goal is not simply desensitization, but long-term tolerance that allows unrestricted consumption later in childhood.
The study followed three high-risk infants who had experienced significant allergic reactions early in life. One presented at six months with peanut allergy and extensive atopic dermatitis, another at ten months with peanut and egg allergies, and a third at one year with cashew allergy and a complex gastrointestinal history.
“These are kids who showed anaphylaxis at 6 months, and instead of just saying ‘You get an EpiPen’ or ‘You have to avoid it,’ we found a way to allow a sustained tolerance so that we could change the rest of their life,” said allergist Rachel Kado.
A critical first step in the protocol is aggressive control of atopic dermatitis. Researchers required that eczema be completely clear before initiating therapy, using a proprietary non-steroidal, ceramide-rich topical designed to restore skin integrity and reduce systemic inflammation.
Oral introduction begins under close medical supervision, with carefully spaced doses and observation periods. Once a tolerable dose is established, families continue daily dosing at home, returning periodically for supervised escalation. This stepwise process continues until the child can tolerate three whole raw peanuts or cashews.
At that point, the protocol transitions to roasted nuts, which are more allergenic due to protein changes during processing. Researchers believe this progression may help strengthen immune regulation during a critical window of early-life immune development.
“If we just change the menu a little bit, and we give them the raw form first… we really could change the future to come with food allergy,” Kado said.
All three infants ultimately achieved sustained, medication-free tolerance. By age four, each child was able to consume peanuts or cashews freely, without restriction or adverse reactions.
Notably, none of the participants required biologics or other immune-modulating therapies during treatment—an important distinction from many emerging food allergy interventions.
Researchers caution that the findings are based on a very small sample and require validation in larger, prospective trials. Still, they say the results highlight a potential new pathway for treating infants who do not respond to or qualify for existing early-introduction strategies.
“This is the renaissance of food allergy,” Kado said. “We have an alternative that could change your life.”
